Europska Unija - hrvatski - EMA (European Medicines Agency)

teva gmbh - dimetil fumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Europska Unija - hrvatski - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheal sredstva, uzročnika crijevnih protuupalnih / antiinfective - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Europska Unija - hrvatski - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europska Unija - hrvatski - EMA (European Medicines Agency)

ratiopharm gmbh - paklitaksela - neoplazme dojki - antineoplastična sredstva - pazenir монотерапия indiciran za liječenje метастатического raka dojke kod odraslih pacijenata, koji ne prizemlju, kuhinju, blagovaonu-linija za obradu metastatic bolesti, a za koga standardni, антрациклин-sadrži terapija nije naveden. pazenir u kombinaciji s карбоплатином indiciran za prvu liniju liječenja немелкоклеточного raka pluća kod odraslih pacijenata koji nisu kandidati na potencijalno ljekovita kirurgije i/ili radioterapije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. za daljnje informacije o stanju čovjeka epidermalnog faktora rasta receptora 2 (her2), molimo pogledajte odjeljak 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. dodatne informacije o statusu her2 potražite u odjeljku 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

fresenius medical care deutschland gmbh, else kröner str.1, bad homburg, njemačka - kalcijev klorid dihidrat natrijev klorid natrijev hidrogenkarbonat magnezijev klorid heksahidrat glukoza hidrat - otopina za peritonejsku dijalizu - urbroj: otopina pripremljena za uporabu sadrži: kalcijev klorid dihidrat 0,1838 g/l, natrijev klorid 5,786 g/l, natrijev hidrogenkarbonat 2,940 g/l, magnezijev klorid heksahidrat 0,1017 g/l, glukoza hidrat 46,75 g/l (42,5 g glukoze), što odgovara iona ca2+ 1,25 mmol/l, iona na+ 134 mmol/l, iona mg 2+ 0,5 mmol/l, iona cl- 103,5 mmol/l, iona hco3- 34 mmol/l, glukoze 235,9 mmol/l.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

fresenius medical care deutschland gmbh, else kröner str.1, bad homburg, njemačka - kalcijev klorid dihidrat - otopina za infuziju - 100 mmol/l - urbroj: 1000 ml otopine sadrži 14,7 g kalcijeva klorida dihidrata, što odgovara 100 mmol kalcija i 200 mmol klorida.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

fresenius medical care deutschland gmbh, else kröner str.1, bad homburg, njemačka - kalcijev klorid dihidrat natrijev klorid natrijev hidrogenkarbonat magnezijev klorid heksahidrat glukoza hidrat - otopina za peritonejsku dijalizu - urbroj: otopina pripremljena za uporabu sadrži: kalcijev klorid dihidrat 0,1838 g/l, natrijev klorid 5,786 g/l, natrijev hidrogenkarbonat 2,940 g/l, magnezijev klorid heksahidrat 0,1017 g/l, glukoza hidrat 16,5 g/l (15,0 g glukoze), što odgovara iona ca2+ 1,25 mmol/l, iona na+ 134 mmol/l, iona mg 2+ 0,5 mmol/l, iona cl- 103,5 mmol/l, iona hco3- 34 mmol/l, glukoze 83,25 mmol/l.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

fresenius medical care deutschland gmbh, else kröner str.1, bad homburg, njemačka - kalcijev klorid dihidrat natrijev klorid natrijev hidrogenkarbonat magnezijev klorid heksahidrat glukoza hidrat - otopina za peritonejsku dijalizu - urbroj: otopina pripremljena za uporabu sadrži: kalcijev klorid dihidrat 0,1838 g/l, natrijev klorid 5,786 g/l, natrijev hidrogenkarbonat 2,940 g/l, magnezijev klorid heksahidrat 0,1017 g/l, glukoza hidrat 25,0 g/l (22,73 g glukoze), što odgovara iona ca2+ 1,25 mmol/l, iona na+ 134 mmol/l, iona mg 2+ 0,5 mmol/l, iona cl- 103,5 mmol/l, iona hco3- 34 mmol/l, glukoze 126,1 mmol/l.